TY - JOUR
T1 - Rapid and transient activation of the ERK MAPK signalling pathway by macrophage migration inhibitory factor (MIF) and dependence on JAB1/CSN5 and Src kinase activity
AU - Lue, Hongqi
AU - Kapurniotu, Aphrodite
AU - Fingerle-Rowson, Günter
AU - Roger, Thierry
AU - Leng, Lin
AU - Thiele, Michael
AU - Calandra, Thierry
AU - Bucala, Richard
AU - Bernhagen, Jürgen
N1 - Funding Information:
We thank M. Dewor for help with the pull-down experiments, M. Cobb for the dnERK construct, and F. Schaper for the SYF cells. We thank E. Bianchi, B. Lüscher and H. Fünfzig for helpful discussions. This work was supported by grant number SFB 542/TP-A7 of the Deutsche Forschungsgemeinschaft (DFG) to J.B., by NIH grants AI43210 and AR49610 to R.B., by a grant from the Leenaards Foundation to T.R., and by grants from the Swiss National Science Foundation to T.C. (3100-066972.01) as well as the Bristol Myers Squibb Foundation, the Leenaards Foundation, and the Santos-Suarez Foundation for Medical Research (T.C.). T.C. is a recipient of a career award from the Leenaards Foundation.
PY - 2006/5
Y1 - 2006/5
N2 - Macrophage migration inhibitory factor (MIF) is a 12.5 kD polypeptide that serves as a critical regulator of cell functions such as gene expression, proliferation or apoptosis. However, the signal transduction pathways through which MIF takes part in cellular regulation are only incompletely understood. MIF leads to CD74-dependent "sustained" activation of ERK1/2 MAPK, but MIF's role in "transient" ERK activation and the involved upstream pathways are unknown. Here we report that the transient ERK pathway was markedly activated by MIF. This effect involved the phosphorylation and activation of Raf-1, MEK, ERK, and Elk-1. Of note, rapid and transient ERK phosphorylation by MIF was measurable in MIF-deficient cells, suggesting that MIF acted in a non-autocrine fashion. Applying the inhibitor genistein, a tyrosine kinase (TPK) activity was identified as a critical upstream signalling event in MIF-induced transient ERK signalling. Experiments using the Src kinase inhibitor PP2 indicated that the involved TPK was a Src-type tyrosine kinase. A role for an upstream Src kinase was proven by applying Src-deficient cells which did not exhibit transient ERK activation upon treatment with MIF, but in which MIF-induced ERK signalling could be restored by re-expressing Src. Intriguingly, JAB1/CSN5, a signalosome component, cellular binding protein of MIF and regulator of cell proliferation and survival, had a marked, yet dual, effect on MIF-induced ERK signalling. JAB1 overexpression inhibited sustained, but not transient, ERK phosphorylation. By contrast, JAB1-knock-down by siRNA revealed that minimum JAB1 levels were necessary for transient activation of ERK by MIF. In conclusion, MIF rapidly and transiently activates the ERK pathway, an effect that has not been recognized previously. This signalling pathway involves the upstream activation of a Src-type kinase and is co-regulated by the cellular MIF binding protein JAB1/CSN5. Our study thus has unravelled a novel MIF-driven signalling pathway and an intricate regulatory system involving extra- and possibly intracellular MIF, and which likely critically participates in controlling cell proliferation and survival.
AB - Macrophage migration inhibitory factor (MIF) is a 12.5 kD polypeptide that serves as a critical regulator of cell functions such as gene expression, proliferation or apoptosis. However, the signal transduction pathways through which MIF takes part in cellular regulation are only incompletely understood. MIF leads to CD74-dependent "sustained" activation of ERK1/2 MAPK, but MIF's role in "transient" ERK activation and the involved upstream pathways are unknown. Here we report that the transient ERK pathway was markedly activated by MIF. This effect involved the phosphorylation and activation of Raf-1, MEK, ERK, and Elk-1. Of note, rapid and transient ERK phosphorylation by MIF was measurable in MIF-deficient cells, suggesting that MIF acted in a non-autocrine fashion. Applying the inhibitor genistein, a tyrosine kinase (TPK) activity was identified as a critical upstream signalling event in MIF-induced transient ERK signalling. Experiments using the Src kinase inhibitor PP2 indicated that the involved TPK was a Src-type tyrosine kinase. A role for an upstream Src kinase was proven by applying Src-deficient cells which did not exhibit transient ERK activation upon treatment with MIF, but in which MIF-induced ERK signalling could be restored by re-expressing Src. Intriguingly, JAB1/CSN5, a signalosome component, cellular binding protein of MIF and regulator of cell proliferation and survival, had a marked, yet dual, effect on MIF-induced ERK signalling. JAB1 overexpression inhibited sustained, but not transient, ERK phosphorylation. By contrast, JAB1-knock-down by siRNA revealed that minimum JAB1 levels were necessary for transient activation of ERK by MIF. In conclusion, MIF rapidly and transiently activates the ERK pathway, an effect that has not been recognized previously. This signalling pathway involves the upstream activation of a Src-type kinase and is co-regulated by the cellular MIF binding protein JAB1/CSN5. Our study thus has unravelled a novel MIF-driven signalling pathway and an intricate regulatory system involving extra- and possibly intracellular MIF, and which likely critically participates in controlling cell proliferation and survival.
KW - CSN
KW - Cytokine
KW - ERK signalling
KW - JAB1
KW - MAPK
KW - MIF
KW - Signalosome
KW - Src kinase
UR - http://www.scopus.com/inward/record.url?scp=30944438465&partnerID=8YFLogxK
U2 - 10.1016/j.cellsig.2005.06.013
DO - 10.1016/j.cellsig.2005.06.013
M3 - Article
C2 - 16122907
AN - SCOPUS:30944438465
SN - 0898-6568
VL - 18
SP - 688
EP - 703
JO - Cellular Signalling
JF - Cellular Signalling
IS - 5
ER -